Is Universal Patient Access to Fulvestrant in Hormone Receptor-positive Advanced Breast Cancer Justified? A UK Retrospective Multicentre Study

Purpose: Fulvestrant is a selective oestrogen receptor (ER) downregulator used to treat postmenopausal women with hormone receptor-positive advanced breast cancer. Given that patient access to this drug across the UK is variable, we sought to investigate its efficacy.

Source: Clinical Oncology - July 8, 2020 Category: Radiology Authors: A. Lerner, K. Keshwani, B. Sanderson, R.E. Board, M. Flynn, E. Sharkey, A. Okines, A. Konstantis, R. Roylance, D. Hanna, J. King, R. Murphy, F. Rehman, A. Guppy, C. Westbury, E. Takeuchi, E. Spurrell, F. Raja Source Type: research